New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
08:22 EDTTXMD, RTRXRetrophin CEO in scandal over Twitter use, TheStreet reports
Retrophin has placed the company's social media activity on "lockdown" following questionable tweets from CEO Martin Shkreli, including one that seemed to hint at a Retrophin acquisition of an approved drug from a private company, reported TheStreet's Adam Feuerstein. The social media blackout also follows the discovery that employees were using Twitter aliases to promote Retrophin and pitch short-sale recommendations of other stocks, including a tweet that singled out TherapeuticsMD (TXMD), the report added. Reference Link
News For RTRX;TXMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
06:06 EDTRTRXGoldman Sachs reports 5.4% passive stake in Retrophin
The Goldman Sachs Group reported a 5.4% stake in biopharmaceutical company Retrophin. Goldman owns over 1.94M shares of the company focused on diseases affecting children, including focal segmental glomerulosclerosis and pantothenate kinase-associated neurodegeneration. Retrophin closed yesterday down 77c to $14.16.
January 27, 2016
11:51 EDTTXMDTherapeuticsMD management to meet with Jefferies
Subscribe for More Information
January 26, 2016
13:06 EDTTXMDTherapeuticsMD management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use